Products - Endometrial cancers | Topic | NICE

Showing 6 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 September 2025
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
13 March 2026
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with carboplatin and paclitaxel for untreated advanced or recurrent endometrial cancer [ID6381]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC